Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$462.08M+32.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul Manning
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Employees
- 4,070
- Beta
- 0.83
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 5.61
Financials
Revenue
$462.08M+32.2%Net Income
$51.36M+44.2%EBITDA
$92.59M+46.9%Free Cash Flow
$9.69M-62.8%EPS (diluted)
$1.20+51.9%Shares Outstanding (diluted)
42.71M-4.7%Operating Expenses
$96.10MCash & Debt
$31.02MReturn of Capital
$17.44MRevenue by Segment (annual)
$1.23BDividend per Share
$0.41Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.61B | $134.49M | $3.18 |
| 2024 | $1.56B | $124.67M | $2.96 |
| 2023 | $1.46B | $93.39M | $2.22 |
| 2022 | $1.44B | $140.89M | $3.36 |
| 2021 | $1.38B | $118.75M | $2.82 |
| 2020 | $1.33B | $109.47M | $2.59 |
| 2019 | $1.32B | $82.05M | $1.94 |
| 2018 | $1.39B | $157.36M | $3.71 |
| 2017 | $1.36B | $89.60M | $2.05 |
| 2016 | $1.38B | $126.26M | $2.84 |
| 2015 | $1.38B | $106.78M | $2.33 |
| 2014 | $1.45B | $73.65M | $1.52 |
| 2013 | $1.47B | $113.30M | $2.28 |
| 2012 | $1.46B | $123.91M | $2.50 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SXT's reported EPS growth of 1.9% a year over 13 years.
- EPS in 5 years
- $3.50
- Implied price
- $104.95
- Return from $131.41
- -4.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $52.18 — -60.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 25 | 30 | 35 | 40 |
|---|---|---|---|---|---|
| -8.1% | -20.5% | -16.9% | -13.8% | -11.1% | -8.7% |
| -3.1% | -16.2% | -12.3% | -9.1% | -6.2% | -3.7% |
| 1.9% | -11.8% | -7.8% | -4.4% | -1.4% | 1.3% |
| 6.9% | -7.5% | -3.3% | 0.3% | 3.4% | 6.2% |
| 11.9% | -3.2% | 1.2% | 5.0% | 8.3% | 11.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80-36.00%Social Signal Score
Mentions (3)
- Newsprnewswire.com·5h ago·Negative
China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per sha…
View source ↗ - 4chan /biz/biz·8d ago·Neutral
My fellow SXT baggies, when will it be our turn?
View source ↗ - Newszacks.com·27d ago·Positive
Sensient (SXT) Upgraded to Strong Buy: Here's Why Sensient (SXT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗
Earnings
Fri, Oct 30(in 3 weeks)
Consensus estimate $1.09 per share
Typical surprise +6.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 24$1.20 vs $1.03beat
- Fri, Apr 24$1.04 vs $0.80beat
- Fri, Feb 13$0.72 vs $0.78miss
- Fri, Oct 31$0.96 vs $0.79beat
- Fri, Jul 25$0.94 vs $0.88beat
- Fri, Apr 25$0.86 vs $0.82beat
Estimates and results for SXT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SXT officers and directors.
- Bought
- $294k
- Sold
- $234.2m
3 trades
9 trades
- Ferruzzi Mariosold
- Hoang Thierrysold
- Hoang Thierrysold
- Morris Steven Bsold
- Winder Pte. Ltd.sold
- Whitelaw Essiesold
- Whitelaw Essiesold
- Plautz David J.bought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.